Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11342700 | 0.92 | APOBEC3G (0.38) | APOBEC3GTDP1CYP2A6EPHX1TSHR | |
| SCHEMBL11941054 | 0.81 | CTSB (0.41) | TDP1PKMKMT2AKDM4EHPGD | |
| SCHEMBL14465955 | 0.80 | CYSLTR2 (0.36) | PKMKMT2A | |
| SCHEMBL23662548 | 0.79 | PKM (0.38) | APOBEC3GPKMKMT2AEPHX1KDM4E | |
| SCHEMBL29865909 | 0.79 | PKM (0.38) | APOBEC3GPKMKMT2AEPHX1KDM4E | |
| SCHEMBL8378247 | 0.78 | TDP1 (0.34) | TDP1 | |
| SCHEMBL29865849 | 0.77 | EPHX1 (0.35) | APOBEC3GPKMKMT2AEPHX1KDM4E | |
| SCHEMBL9381164 | 0.77 | EPHX1 (0.35) | APOBEC3GPKMKMT2AEPHX1KDM4E | |
| SCHEMBL9505479 | 0.76 | — | — | |
| SCHEMBL9505472 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307449-B1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMA (JP) | 2005-12-07 | — | — | EP | disclosed |
| EP-1492863-A1 | TEXTILE CLEANING AGENT WHICH IS GENTLE ON TEXTILES | Henkel Kommanditgesellschaft auf Aktien (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-6653313-B2 | For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-25 | — | — | US | disclosed |
| WO-2003085074-A1 | TEXTILE CLEANING AGENT WHICH IS GENTLE ON TEXTILES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2003-10-16 | — | — | WO | disclosed |
| EP-1307449-A1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | KAWAMURA MITSUHIRO (US) | 2002-10-31 | — | — | US | disclosed |
| WO-2002012235-A1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | APOBEC3G 4805/4885TDP1 3452/4885PKM 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.